Current Osteoporosis Reports

, Volume 12, Issue 3, pp 243–251

Sclerosing Bone Dysplasias: Leads Toward Novel Osteoporosis Treatments

  • Igor Fijalkowski
  • Eveline Boudin
  • Geert Mortier
  • Wim Van Hul
Skeletal Genetics (ML Johnson and S Ralston, Section Editors)

DOI: 10.1007/s11914-014-0220-5

Cite this article as:
Fijalkowski, I., Boudin, E., Mortier, G. et al. Curr Osteoporos Rep (2014) 12: 243. doi:10.1007/s11914-014-0220-5

Abstract

Sclerosing bone dysplasias are a group of rare, monogenic disorders characterized by increased bone density resulting from the disturbance in the fragile equilibrium between bone formation and resorption. Over the last decade, major contributions have been made toward better understanding of the pathogenesis of these conditions. These studies provided us with important insights into the bone biology and yielded the identification of numerous drug targets for the prevention and treatment of osteoporosis. Here, we review this heterogeneous group of disorders focusing on their utility in the development of novel osteoporosis therapies.

Keywords

Sclerosing bone dysplasia Osteopetrosis Pycnodysostosis High bone mass phenotype Sclerosteosis Van Buchem disease Craniodiaphyseal dysplasia Craniometaphyseal dysplasia Camurati-Engelmann disease Osteopoikilosis Raine syndrome Paget’s disease of bone Ostaoectasia with hyperphosphatasia, Familial expansile osteolysis Expansile skeletal hyperphosphatasia Osteoporosis Treatment 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Igor Fijalkowski
    • 1
  • Eveline Boudin
    • 1
  • Geert Mortier
    • 1
  • Wim Van Hul
    • 1
  1. 1.Department of Medical GeneticsUniversity and University Hospital of AntwerpEdegemBelgium

Personalised recommendations